Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00119392 · OUTCOME

Overall and Progression-free Survival

Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma · Source last updated 2018-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent
Interval / dispersion
95% Confidence Interval
Time frame
Up to 8 years

What was measured

Kaplan-Meier estimates for overall survival (OS) and progression free survival (PFS) assessed at two years.

Groups in this outcome

Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)

See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)40

Reported measurements

Overall survival
Values in percent · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)54Not reported3768Not reported
Progression free survival
Values in percent · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)31Not reported1648Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        37
        upper Limit
        68
        value
        54
    title
    Overall survival
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        16
        upper Limit
        48
        value
        31
    title
    Progression free survival
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
description
Kaplan-Meier estimates for overall survival (OS) and progression free survival (PFS) assessed at two years.
dispersion Type
95% Confidence Interval
groups
  1. description
    See Detailed Description rituximab: Given IV cyclosporine: Given orally fludarabine phosphate: Given IV mycophenolate mofetil: Given orally yttrium Y 90 ibritumomab tiuxetan: Given IV peripheral blood stem cell transplantation: Undergo transplantation allogeneic hematopoietic stem cell transplantation: Undergo transplantation total-body irradiation: Undergo TBI
    id
    OG000
    title
    Treatment (90Y Ibritumomab Tiuxetan, Hematopoietic Transplant)
param Type
NUMBER
reporting Status
POSTED
time Frame
Up to 8 years
title
Overall and Progression-free Survival
type
SECONDARY
unit Of Measure
percent

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice